Anticorps Polyclonal de lapin anti-HER2/ErbB2

• Phare
• Validé par KD/KO

HER2/ErbB2 Polyclonal Antibody for WB, IHC, IF-Fro, IP, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris et plus (1)

Applications

WB, IHC, IF-Fro, IP, ELISA

Conjugaison

Non conjugué

Publications(81)

Avis (1)

N° de cat : 18299-1-AP

Synonymes

ERBB2, CD340, HER 2, HER 2/neu, HER2

---

Galerie de données de validation

• 

  WB analysis using 18299-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 18299-1-AP

  WB result of HER2/ErbB2 antibody (18299-1-AP; 1:20000; incubated at room temperature for 1.5 hours) with sh-Control and sh-HER2/ErbB2 transfected MCF-7 cells.

• 

  WB analysis of SGC-7901 using 18299-1-AP

  SGC-7901 cells were subjected to SDS PAGE followed by western blot with 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  IP experiment of SGC-7901 using 18299-1-AP

  IP result of anti-HER2/ErbB2 (IP:18299-1-AP, 5ug; Detection:18299-1-AP 1:500) with SGC-7901 cells lysate 2400ug.

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:600 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:600 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human ovary cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human ovary cancer tissue slide using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:400 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:100 (under 10x lens).

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:100 (under 40x lens).

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 18299-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:50 (under 40x lens).

• 

  IF Staining of mouse breast cancer using 18299-1-AP

  Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded mouse breast cancer using HER2/ErbB2 antibody (18299-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).

---

Applications testées

• Résultats positifs en WB: cellules 4T1, cellules HeLa, cellules MCF-7, cellules SGC-7901
• Résultats positifs en IP: cellules SGC-7901
• Résultats positifs en IHC: tissu de cancer du sein humain, human ovary cancer tissue; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF-Fro: mouse breast cancer,

Dilution recommandée

• Western Blot (WB): WB : 1:2000-1:12000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:300-1:1200
• Immunofluorescence (IF)-FRO: IF-FRO : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 3 publications below
• WB: See 60 publications below
• IHC: See 17 publications below
• IF: See 7 publications below
• IP: See 1 publications below

Informations sur le produit

18299-1-AP cible HER2/ErbB2 dans les applications de WB, IHC, IF-Fro, IP, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
• Masse moléculaire calculée: 138 kDa
• Poids moléculaire observé: 185 kDa
• Numéro d’acquisition GenBank: BC167147
• Symbole du gène: HER2/ErbB2
• Identification du gène (NCBI): 2064
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.

Publications

Species	Application	Title
human	IF	Signal Transduct Target Ther; Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis; Authors - Chuan Yang
human	WB	Cell Metab; Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity; Authors - Zilong Zhang
human	IHC	Cell Res; Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.; Authors - Daisong Wang
mouse	WB	Small; Efficient Delivery of GSDMD-N mRNA by Engineered Extracellular Vesicles Induces Pyroptosis for Enhanced Immunotherapy; Authors - Yuqi Xing
human	IHC	Nat Commun; Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.; Authors - Yunhua Liu
human		J Nanobiotechnology; Accurate HER2 determination in breast cancer: a prominent COF-immobilized enzyme-enhanced electrochemical aptasensor employing 4-acetamidophenol as an efficient mediator; Authors - Yue Zhang

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.

---

FH

Vanina (Verified Customer) (07-28-2021)

MDA-MB-453 cell line was transfected with different concentrations of HER2/Erbb2 siRNA for 48h. Western blot using HER2/Erbb2 rabbit Proteintech antibody (18299-1-AP) at 1:2,000 dillution confirms the HER2/Erbb2 knockdown.

• Applications: Western Blot
• Primary Antibody Dilution: 1:2,000
• Cell Tissue Type: MDA-MB-453 breast cancer cell line

HER2/ErbB2 Antibody Western Blot validation (1:2,000 dilution) in MDA-MB-453 breast cancer cell line (Cat no:18299-1-AP)

{{ptg:RelatedPrimaryAntibodies}}